0NWK Stock Chart & Stats
€0.06
€0.00(0.00%)
At close: 4:00 PM EST
€0.06
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.06 - €0.98
Previous CloseN/A
Volume0.00
Average Volume (3M)57.92K
Market Cap
€423.81M
Enterprise Value€77.01M
Total Cash (Recent Filing)€1.05M
Total Debt (Recent Filing)€7.61M
Price to Earnings (P/E)―
Beta0.74
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding499,448,300
10 Day Avg. Volume9,812
30 Day Avg. Volume57,918
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)10.27
Price to Sales (P/S)8.28
P/FCF Ratio40.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue ReboundThe strong 2025 revenue rebound indicates improving commercial, licensing, or development-related activity. Sustained growth would strengthen the company’s ability to fund oncology programs and reduce reliance on external capital.
Strong Gross MarginsHigh gross margins provide economic support for the small-molecule oncology model if revenue expands. They suggest that incremental revenue could contribute meaningfully toward research spending and eventual operating-cost absorption.
Improved Cash GenerationThe shift to positive operating and free cash flow is an important operational improvement after several years of cash burn. If maintained, it could extend funding capacity and lower dependence on repeated financing.
Bears Say
Persistent Net LossesThe continuing net loss shows that the business has not yet achieved sustainable profitability despite improved revenue and margins. Ongoing losses can consume capital and limit the resources available for advancing clinical programs.
Elevated LeverageHigh leverage materially constrains financial flexibility for a clinical-stage biotechnology company. Debt obligations may compete with research funding and increase dependence on successful financing or development outcomes.
Volatile Financial BaseThe sharp changes in equity and declining assets indicate an unstable capital base. This weakens resilience across development cycles and suggests that future investment in clinical programs may require additional external funding.
Valerio Therapeutics News
0NWK FAQ
What was Valerio Therapeutics’s price range in the past 12 months?
Valerio Therapeutics lowest share price was €0.06 and its highest was €0.98 in the past 12 months.
What is Valerio Therapeutics’s market cap?
Valerio Therapeutics’s market cap is €423.81M.
When is Valerio Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Valerio Therapeutics’s earnings last quarter?
Currently, no data Available
Is Valerio Therapeutics overvalued?
According to Wall Street analysts Valerio Therapeutics’s price is currently Overvalued.
Does Valerio Therapeutics pay dividends?
Valerio Therapeutics does not currently pay dividends.
What is Valerio Therapeutics’s EPS estimate?
Valerio Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Valerio Therapeutics have?
Valerio Therapeutics has 499,448,300 shares outstanding.
What happened to Valerio Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Valerio Therapeutics?
Currently, no hedge funds are holding shares in GB:0NWK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Valerio Therapeutics
Headquartered in Paris, France, and founded in 1997, Valerio Therapeutics S.A. (known as Onxeo SA until June 2023) is a clinical-stage biotechnology company dedicated to the global research and development of oncology treatments. Their focus is on targeting the DNA repair processes crucial for tumor survival. The company's offerings include Beleodaq, an approved medication for peripheral T-cell lymphoma. Their development pipeline features AsiDNA, which is progressing through Phase 1 clinical trials for metastatic melanoma and is also being evaluated for relapsed ovarian cancer through a research collaboration with Gustave Roussy. Furthermore, Valerio Therapeutics is advancing OX401, a preclinical program targeting DNA damage response and immuno-oncology, along with its proprietary platON decoy oligonucleotide platform. The firm also holds a licensing agreement with Acrotech Biopharma LLC.
Technical Analysis
Innate Pharma SA
―
Transgene
―
OSE Immunotherapeutics SA
―
GenSight Biologics SA
―
Cellectis SA
―